Environmental

Hoth Therapeutics appears structurally lighter on direct environmental exposure than manufacturing peers because its biotech model is research-led rather than resource- or emissions-intensive.

The provided metrics show no meaningful R&D intensity relative to revenue, which limits evidence of environmental process investment compared with larger peers that disclose more operational footprint management.

With no disclosed debt burden and minimal capital intensity in the supplied data, the company likely faces fewer near-term environmental compliance pressures than industrial or lab-scale peers.

Environmental disclosure depth appears limited in the available information, which weakens peer-relative transparency even if the underlying operational footprint is likely modest.

Social

As a clinical-stage biotech, Hoth’s social profile is primarily shaped by patient safety and trial conduct, but the available data provide little evidence of stronger-than-peer disclosure.

The absence of reported stock-based compensation intensity may indicate less dilution-driven workforce pressure than some development-stage peers, though disclosure is insufficient to confirm a durable advantage.

Because the company is early-stage and research-focused, its social risk is more concentrated in clinical governance and stakeholder trust than in large-scale labor or supply-chain issues.

Relative to better-disclosed biotech peers, the limited metrics available constrain confidence in social oversight, keeping the score in the moderate range.

Governance

The zero reported stock-based compensation to revenue suggests limited visible compensation burden, but it also reflects sparse disclosure rather than clearly superior governance versus peers.

A net debt to EBITDA ratio of 0.59 implies manageable leverage, which reduces creditor pressure and supports governance flexibility relative to more indebted peers.

However, the absence of meaningful profitability and cash-flow metrics in the supplied data limits assessment of board discipline, capital allocation, and long-term oversight quality.

Overall governance positioning appears neither clearly weak nor strong versus peers because the available information is too limited to demonstrate a structural advantage.

Overall Score

Hoth Therapeutics screens as a moderate ESG performer versus peers because its likely low operating footprint and manageable leverage are offset by limited disclosure depth.

Score Driver: Limited ESG Disclosure Prevents A Stronger Peer-Relative Assessment Despite A Likely Modest Environmental Footprint.